Marko Hyvönen

6.2k total citations
97 papers, 4.6k citations indexed

About

Marko Hyvönen is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Marko Hyvönen has authored 97 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 13 papers in Oncology and 12 papers in Cell Biology. Recurrent topics in Marko Hyvönen's work include Protein Kinase Regulation and GTPase Signaling (15 papers), TGF-β signaling in diseases (12 papers) and Chemical Synthesis and Analysis (11 papers). Marko Hyvönen is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (15 papers), TGF-β signaling in diseases (12 papers) and Chemical Synthesis and Analysis (11 papers). Marko Hyvönen collaborates with scholars based in United Kingdom, Germany and United States. Marko Hyvönen's co-authors include Matti Saraste, Leevi Kääriäinen, Johan Peränen, Hartmut Oschkinat, Gerhard W. Fischer, David R. Spring, Elena Baraldi, Florian Hollfelder, Ashok R. Venkitaraman and M Rikkonen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Marko Hyvönen

95 papers receiving 4.5k citations

Peers

Marko Hyvönen

ONCOL

IMMUN

M. Teresa Pisabarro Germany

Bing Yang China

Jean‐Paul Mornon France

Roland S. Annan United States

Ouathek Ouerfelli United States

Daniela Marasco Italy

Olli T. Pentikäinen Finland

Paul J. Boersema Netherlands

Andrew G. Stephen United States

Makoto Adachi Japan

M. Teresa Pisabarro Germany

Marko Hyvönen

3.6k ×1.1

1.1k ×1.5

363 ×0.7

537 ×1.1

ONCOL

380 ×1.1

IMMUN

Citations per year, relative to Marko Hyvönen Marko Hyvönen (= 1×) peers M. Teresa Pisabarro

Countries citing papers authored by Marko Hyvönen

Since Specialization

Citations

This map shows the geographic impact of Marko Hyvönen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marko Hyvönen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marko Hyvönen more than expected).

Fields of papers citing papers by Marko Hyvönen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marko Hyvönen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marko Hyvönen. The network helps show where Marko Hyvönen may publish in the future.

Co-authorship network of co-authors of Marko Hyvönen

This figure shows the co-authorship network connecting the top 25 collaborators of Marko Hyvönen. A scholar is included among the top collaborators of Marko Hyvönen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marko Hyvönen. Marko Hyvönen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lulla, Aleksei, Matthew I. J. Raybould, Timo N. Kohler, et al.. (2024). Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells. Nature Biotechnology. 43(6). 960–970. 10 indexed citations

Makrecka‐Kuka, Marina, et al.. (2023). Development of isoselenazolium chlorides as selective pyruvate kinase isoform M2 inhibitors. European Journal of Medicinal Chemistry. 257. 115504–115504. 5 indexed citations

Reinecke, Maria, P. Brear, Larsen Vornholz, et al.. (2023). Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors. Nature Chemical Biology. 20(5). 577–585. 35 indexed citations

Zuazua‐Villar, Pedro, Andrew J. Counsell, Stephen J. Walsh, et al.. (2023). A recombinant approach for stapled peptide discovery yields inhibitors of the RAD51 recombinase. Chemical Science. 14(47). 13915–13923. 3 indexed citations

Stanway, Steven J., Yuliya Demydchuk, G.A. Bezerra, et al.. (2023). Structure-Guided Chemical Optimization of Bicyclic Peptide (Bicycle) Inhibitors of Angiotensin-Converting Enzyme 2. Journal of Medicinal Chemistry. 66(14). 9881–9893. 3 indexed citations

Karusheva, Yanislava, Alexander Mörseburg, Peter Barker, et al.. (2022). The Common H202D Variant in GDF-15 Does Not Affect Its Bioactivity but Can Significantly Interfere with Measurement of Its Circulating Levels. The Journal of Applied Laboratory Medicine. 7(6). 1388–1400. 19 indexed citations

Iegre, Jessica, Claudio D’Amore, P. Brear, et al.. (2022). Development of small cyclic peptides targeting the CK2α/β interface. Chemical Communications. 58(30). 4791–4794. 3 indexed citations

Ramachandran, Anassuya, Dessislava Malinova, Ilaria Gori, et al.. (2021). Pathogenic ACVR1 ^R206H activation by Activin A‐induced receptor clustering and autophosphorylation. The EMBO Journal. 40(14). e106317–e106317. 20 indexed citations

Lindenburg, Laurens H., Fabrice Gielen, Pedro Zuazua‐Villar, et al.. (2021). Improved RAD51 binders through motif shuffling based on the modularity of BRC repeats. Proceedings of the National Academy of Sciences. 118(46). 14 indexed citations

10.

Bellou, Sofia, Eleni Bagli, Eleftherios Kostaras, et al.. (2021). Embryonic stem cells are devoid of macropinocytosis, a trafficking pathway for activin A in differentiated cells. Journal of Cell Science. 134(13). 3 indexed citations

11.

Iegre, Jessica, et al.. (2021). Chemical probes targeting the kinase CK2: a journey outside the catalytic box. Organic & Biomolecular Chemistry. 19(20). 4380–4396. 21 indexed citations

12.

Iegre, Jessica, et al.. (2021). Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study. Molecules. 26(7). 1977–1977. 19 indexed citations

13.

Brear, P., et al.. (2020). Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α. Journal of Medicinal Chemistry. 63(21). 12786–12798. 16 indexed citations

14.

Babii, Oleg, Sergii Afonin, Wenshu Xu, et al.. (2020). Diarylethene moiety as an enthalpy-entropy switch: photoisomerizable stapled peptides for modulating p53/MDM2 interaction. Organic & Biomolecular Chemistry. 18(28). 5359–5369. 16 indexed citations

15.

Walker, Ryan G., Magdalena Czepnik, Adam Hagg, et al.. (2018). Molecular characterization of latent GDF8 reveals mechanisms of activation. Proceedings of the National Academy of Sciences. 115(5). E866–E875. 29 indexed citations

16.

Cotton, Thomas R., Gerhard W. Fischer, Xuelu Wang, et al.. (2018). Structure of the human myostatin precursor and determinants of growth factor latency. The EMBO Journal. 37(3). 367–383. 49 indexed citations

17.

Iegre, Jessica, Josephine Gaynord, Naomi Robertson, et al.. (2018). Two‐Component Stapling of Biologically Active and Conformationally Constrained Peptides: Past, Present, and Future. Advanced Therapeutics. 1(7). 40 indexed citations

18.

Iegre, Jessica, P. Brear, Claudia De Fusco, et al.. (2018). Second-generation CK2α inhibitors targeting the αD pocket. Chemical Science. 9(11). 3041–3049. 33 indexed citations

19.

Cole, Daniel J., M. Janecek, Maxim Rossmann, et al.. (2017). Computationally-guided optimization of small-molecule inhibitors of the Aurora A kinase–TPX2 protein–protein interaction. Chemical Communications. 53(67). 9372–9375. 12 indexed citations

20.

Hagemann, Anja I.H., et al.. (2009). Rab5-mediated endocytosis of activin is not required for gene activation or long-range signalling in Xenopus. Development. 136(16). 2803–2813. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact